Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Duzallo Approval Opens Gout Opportunity For Ironwood

Aug 21 2017

• By Emily Hayes

FDA approved background, 3D rendering, blue street sign

Related Content

Keeping Track: New Indication For Lucentis; New Lesinurad Application From Ironwood

Jan 06 2017

As Gout Market Opens Up, Experts Await Therapies To Better Lower Uric Acid

Nov 01 2009

Ironwood Buys AstraZeneca's Zurampic As Ideal Linzess Complement

Apr 26 2016

With Zurampic, FDA Again Made Do With Sorry State Of Regulatory Science In Gout

Aug 16 2016

Related Companies

Ironwood Pharmaceuticals, Inc.

Ardea Biosciences, Inc.

AstraZeneca PLC

Takeda Pharmaceutical Co. Ltd.

Horizon Therapeutics plc

Kowa Company, Ltd.

Johnson & Johnson

Swedish Orphan Biovitrum AB

Revive Therapeutics Ltd.

Selecta Biosciences, Inc.

Additional Topics

Approvals Market Intelligence Regulation Inflammation BioPharmaceutical

More from New Products

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window